Premium Nahrungsergänzungsmittel | artgerecht

Cisatracurium – Neuromuscular Blocking Agent

Cisatracurium is a non-depolarizing neuromuscular blocking agent used in anesthesia to relax skeletal muscles and facilitate endotracheal intubation.

Regular tips about health Regular tips about health

Things worth knowing about "Cisatracurium"

Cisatracurium is a non-depolarizing neuromuscular blocking agent used in anesthesia to relax skeletal muscles and facilitate endotracheal intubation.

What is Cisatracurium?

Cisatracurium is a non-depolarizing neuromuscular blocking agent belonging to the benzylisoquinolinium class of compounds. It is one of the ten stereoisomers of atracurium and is approximately three to five times more potent. A key clinical advantage over atracurium is its significantly reduced propensity to cause histamine release, making it better tolerated in a wide range of patients.

Indications

Cisatracurium is used in the following clinical situations:

Endotracheal intubation: Relaxation of laryngeal and respiratory muscles to facilitate placement of a breathing tube.
Surgical muscle relaxation: Maintenance of adequate skeletal muscle relaxation during general anesthesia.
Intensive care unit (ICU) sedation: Short-term muscle relaxation in mechanically ventilated patients, particularly in severe ARDS (Acute Respiratory Distress Syndrome) or to prevent ventilator dyssynchrony.

Mechanism of Action

Cisatracurium acts as a competitive antagonist at nicotinic acetylcholine receptors at the neuromuscular junction. By competitively blocking the binding sites for acetylcholine, it prevents depolarization of the motor end plate and subsequent muscle contraction. The block is dose-dependent and fully reversible.

A distinctive pharmacokinetic feature of cisatracurium is its elimination via Hofmann elimination – a spontaneous, non-enzymatic chemical degradation that occurs at physiological pH and body temperature in the plasma, independent of liver or kidney function. This property makes it particularly suitable for patients with hepatic or renal impairment.

Dosage and Administration

Cisatracurium is administered exclusively by intravenous injection or infusion. Dosing is individualized based on body weight, clinical indication, and patient response:

Intubation dose: Typically 0.15 mg/kg body weight intravenously.
Maintenance dose: Usually 0.03 mg/kg as intermittent bolus or a continuous infusion of 1–2 µg/kg/min.
ICU use: Continuous infusion, titrated according to neuromuscular monitoring.

The clinical duration of action following an intubation dose is approximately 40–75 minutes. Reversal of neuromuscular blockade can be achieved with cholinesterase inhibitors such as neostigmine once spontaneous recovery has begun, or with sugammadex in select cases.

Side Effects

Cisatracurium is generally well tolerated. Potential side effects include:

Cardiovascular: Rarely, fluctuations in blood pressure or bradycardia.
Histamine release: Very rare compared to atracurium; occasional mild skin flushing.
Residual neuromuscular blockade: Postoperative muscle weakness if reversal is inadequate.
Hypersensitivity reactions: Rare allergic reactions have been reported.

Contraindications and Precautions

Cisatracurium is contraindicated in patients with known hypersensitivity to cisatracurium or other benzylisoquinolinium compounds. Special caution is advised in:

Patients with neuromuscular diseases (e.g., myasthenia gravis), who may exhibit increased sensitivity to neuromuscular blocking agents.
Concurrent use of drugs that may potentiate neuromuscular blockade, such as certain aminoglycoside antibiotics or magnesium salts.
Patients with burns or prolonged immobilization, as altered drug sensitivity may occur.

Key Clinical Advantages

Cisatracurium offers several important clinical benefits:

Organ-independent elimination via Hofmann elimination – safe for use in patients with hepatic or renal failure.
Minimal histamine release – superior tolerability compared to atracurium, suitable for atopic patients.
Predictable duration of action – simplifies neuromuscular management in both the operating room and the ICU.

References

Naguib M, Lien CA. Pharmacology of muscle relaxants and their antagonists. In: Miller's Anesthesia. 8th ed. Elsevier; 2015.
European Medicines Agency (EMA): Nimbex (Cisatracurium) – Summary of Product Characteristics. Available at: www.ema.europa.eu
Papazian L et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107–1116.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.